Neuland LAB Ltd.

NSE: NEULANDLAB · Pharmaceuticals · sector

₹19,055.00NSE close 2026-10-26

Key numbers

Market cap₹24,582 cr

Price₹19,055.00

52w high / low₹24,225 / ₹11,500

P/E49.1xSector median 27.9x

P/B13.1xSector median 2.9x

Book value₹1,453.0

Dividend yield0.06%Sector median 0.48%

ROE29.3%Sector median 11.7%

ROCE33.6%Sector median 12.3%

OPM32.2%Sector median 14.0%

Debt / equity0.10xSector median 0.16x

EV/EBITDA32.0xSector median 18.6x

Interest cover26.4x

Current ratio2.09x

Sales growth 3y+19.3%Sector median +9.6%

Profit growth 3y+30.6%Sector median +13.3%

PEG1.61x

Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹355 cr vs borrowings ₹197 cr (FY26): cash is higher (net cash).
Operating profit covered interest 26.4x in the last 12 months.
2.32% of the promoters' shares are pledged (0.8% of all shares).
Operating cash flow was below net profit in 3 of the last 5 years (FY26, FY24, FY22).
Revenue was higher than a year earlier in 4 of the last 4 quarters.
Other income was 6% of net profit in the last 12 months.
Debtor days went from 87 (FY24) to 98 (FY26).
Dividend paid in 5 of the last 5 financial years.
Price ₹19,055.00 on 2026-10-26: -21.3% from the 52-week high, +65.7% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹23,545.00 · low ₹10,487.30

Quarterly results

₹ cr	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	311	398	328	293	514	440	776	642
EBITDA	62	142	51	34	156	77	307	223
OPM %	20.0%	35.8%	15.6%	11.8%	30.2%	17.5%	39.6%	34.7%
Other income	4	4	7	8	2	8	12	8
Net profit	33	102	28	14	97	41	213	148
EPS (₹)	25.60	79.18	21.67	10.83	75.49	31.62	165.76	115.10
Revenue YoY					+65.4%	+10.5%	+136.4%	+119.2%
Profit YoY					+194.9%	-60.1%	+664.7%	+962.4%

Consolidated figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY22	FY23	FY24	FY25	FY26	TTM
Revenue	951	1,191	1,559	1,477	2,023	2,372
EBITDA	143	272	463	400	574	763
Net profit	64	164	300	260	364	498
EPS (₹)	49.74	127.45	233.89	202.74	283.71	387.97
Revenue growth		+25.2%	+30.8%	-5.2%	+37.0%	+78.3%
Profit growth		+156.2%	+83.5%	-13.3%	+39.9%	+182.6%
Dividend / share (₹)	3.00	5.00	10.00	14.00	12.00

Compounded growth	3 years	5 years	Last 12 months
Sales	+19.3%	+16.6%	+78.3%
Net profit	+30.6%	+35.2%	+182.6%
EPS	+30.6%	+35.2%	–
Share price	–	+18.0% (2y)	+16.6%

Balance sheet

₹ cr	FY22	FY23	FY24	FY25	FY26
Shareholders' equity	–	994	1,283	1,525	1,874
Borrowings	–	122	83	136	197
Cash & equivalents	–	59	117	366	355
Total assets	–	1,580	1,833	2,180	2,930
Fixed assets	–	457	523	674	892
Capital work in progress	–	41	46	45	210
Investments	–	1	1	2	2
Receivables	–	362	374	316	541
Inventory	–	279	350	386	510
Payables	–	171	192	252	269

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY22	FY23	FY24	FY25	FY26
Cash from operations	59	237	261	317	347
Cash from investing	-94	-62	-150	-298	-424
Cash from financing	38	-136	-69	25	21
Capex	96	66	144	206	397
Free cash flow	-37	171	118	111	-50

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY22	FY23	FY24	FY25	FY26
ROE %	–	16.4%	23.4%	17.1%	19.4%
ROCE %	–	20.5%	30.4%	21.4%	24.8%
Debtor days	–	111	87	78	98
Inventory days	–	213	222	240	247
Payable days	–	131	121	157	130
Cash conversion cycle (days)	–	193	188	161	215
Working capital days	–	99	116	167	139

Shareholding

Holder	% (2026-09-30)
Promoters	32.26%
FIIs	21.93%
DIIs	16.26%
of which Mutual funds	12.45%
of which Insurance	1.35%
Public (non-institutions)	29.55%

Quarter	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters %	32.68%	32.68%	32.68%	32.64%	32.63%	32.63%	32.62%	32.26%

Promoter group	%
Davuluri Ownership Trust (Dr. Davuluri Ramamohan Rao, Mr. Davuluri Sucheth Rao and Mr. Davuluri Saharsh Rao - Trustees)	25.98%
Davuluri Sucheth RAO	2.01%
Ramamohan RAO Davuluri	1.63%
Davuluri Saharsh RAO	1.60%
Davuluri Rohini Niveditha RAO	0.28%
Gannabathula Veeravenkata Satyanarayanamurty	0.24%
Usha Rani Reddy Chevalla	0.17%
Deepthi Davuluri	0.10%
G V V Sriranganayakamma	0.07%
Gannabathula Venkata Krishna Rama RAO	0.05%
Gannabathula UMA Bala	0.05%
Kommula Kamala Tayaramma	0.05%
Davuluri Vijaya RAO	0.04%
Velugubanti S Prasadarao	0.00%
Suryanarayana M Siram	0.00%

Public holders above 1%	%
Malabar India Fund Limited	4.66%
Mukul Mahavir Agrawal	3.12%
HDFC Mutual Fund - HDFC MNC Fund	2.82%
Siddharth Iyer	1.72%
HSBC Mutual Fund - HSBC Small CAP Fund	1.55%
ICICI Prudential S&P BSE 500 ETF	1.53%
Mahindra Manulife Elss TAX Saver Fund	1.52%
Kedia Securities Private Limited	1.01%

49,741 shareholders. Pledged: 2.32% of promoter shares.

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
NEULANDLAB	₹24,582 cr	49.1x	13.1x	29.3%	33.6%	32.2%	+19.3%	0.06%

All 185 companies in Pharmaceuticals →

Dividends & corporate actions

Ex-date	Action	Detail
2026-07-24	Dividend	Dividend - Rs 34 Per Share
2025-07-18	Dividend	Dividend - Rs 12 Per Share
2024-07-12	Dividend	Annual General Meeting/Dividend - Rs 14 Per Share
2023-07-11	Dividend	Annual General Meeting/Dividend - Rs 10 Per Share
2022-07-14	Dividend	Annual General Meeting/Dividend - Rs 5 Per Share
2021-06-29	Dividend	Annual General Meeting/Dividend - Rs 3 Per Share
2020-11-10	Dividend	Interim Dividend - Rs 2 Per Share
2020-07-02	Other	Annual General Meeting
2020-02-18	Dividend	Interim Dividend - Rs 2 Per Share
2019-06-27	Dividend	Annual General Meeting/Dividend - Rs 1.20 Per Share
2018-08-03	Other	Annual General Meeting
2017-12-21	Other	Annual General Meeting (Date Revised)
2016-08-04	Dividend	Annual General Meeting/ Dividend - Rs 2/- Per Share
2015-08-06	Dividend	Annual General Meeting/Dividend Rs 1.50 Per Share
2014-08-13	Rights	Rights Issue 4 : 25 @ Premium Rs 194/- Per Equity Share
2014-06-16	Dividend	Annual General Meeting/Final Dividend Rs.1.50 Per Share And Special Dividend Rs.1.50 Per Share
2013-07-24	Dividend	Annual General Meeting And Dividend Rs.1.20 Per Share
2012-08-03	Other	Annual General Meeting
2012-03-21	Rights	Rights 5:12 @ Premium Rs.35/- Per Share
2011-07-29	Other	Annual General Meeting

Documents

Links go to the original files on the exchange website.

About the company

Manufacturing of Active Pharmaceutical Ingredients: Manufacturing of Active Pharmaceutical Ingredients


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	NEULANDLAB
BSE code	524558
ISIN	INE794A01010
Face value	₹10.0
Incorporated	1984-01-07
Website	www.neulandlabs.com
Plants (India / abroad)	4 / 0

From the company's filings (BRSR FY26).

Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.